Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.41 |
| ▸ | IKBKB | O14920 | 5/20 | 0.35 |
| ▸ | CHUK | O15111 | 4/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | CDK11B | P21127 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.34 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.34 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.34 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22099680 | 0.97 | BRD4 (0.43) | BRD4IKBKBCHUKRIPK1 | |
| SCHEMBL17895187 | 0.91 | BRD4 (0.37) | BRD4IKBKBCHUKSYKTTK | |
| SCHEMBL17895059 | 0.87 | BRD4 (0.40) | BRD4IKBKBCHUKSYKCDK11B | |
| SCHEMBL22099669 | 0.86 | LCK (0.37) | IKBKBCHUKCSNK1DLCK | |
| SCHEMBL22099685 | 0.85 | IKBKB (0.40) | BRD4IKBKBCHUKSYKCSNK1D | |
| SCHEMBL17895202 | 0.85 | BRD4 (0.39) | BRD4IKBKBCHUKSYKTTK | |
| SCHEMBL17895194 | 0.84 | BRD4 (0.39) | BRD4IKBKBCHUKSYKCSNK1D | |
| SCHEMBL22099681 | 0.83 | CSNK1D (0.38) | CSNK1DLCK | |
| SCHEMBL22099689 | 0.82 | BRD4 (0.47) | BRD4IKBKBCHUKTTKCSNK1D | |
| SCHEMBL17895067 | 0.82 | BRD4 (0.37) | BRD4IKBKBCHUKSYKTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | claimed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | BRD4 222/4885IKBKB 1832/4885CHUK 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.